Omeros Corporation

Research Omeros Corporation (OMER) on Bullrun: valuation model: 15.6% undervalued, market cap USD 717.24M, P/E 11.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerOMER
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal15.6% undervalued
• Market capUSD 717.24M
• P/E11.6
• Financial periodFY2025
• Net income-USD 3.35M
• Free cash flow-USD 116.16M

Valuation Snapshot

Bullrun's latest valuation model marks Omeros Corporation as 15.6% undervalued; latest market cap is USD 717.24M; P/E is 11.6.

About Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Frequently asked questions

Is Omeros Corporation overvalued or undervalued?

Bullrun's valuation model currently marks Omeros Corporation as 15.6% undervalued.

What is Omeros Corporation's market cap?

Omeros Corporation's market capitalization is USD 717.24M.

What is Omeros Corporation's P/E ratio?

Omeros Corporation's price-to-earnings (P/E) ratio is 11.6.

What does Omeros Corporation do?

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.